<code id="z5ntm"></code><u id="z5ntm"></u>
    1. <b id="z5ntm"></b>
    2. 在線訂購
       

      Comprehensive information
      Corporate announcements
      Industry dynamic
      Product dynamic
      Comprehensive information

      5 new drugs approved by the U.S. FDA in June
      2015-07-07         

      Trade name

      General name

      Action

      ResearchCompany

       

      ApprovedDay

      Kengreal

      Cangrelor

      Antiplatelet agents

      Medicines Co

      06/22/2015

      Metaxalone

      Metaxalone

      Adjuvant therapy for relieving pain

      Corepharma

      06/01/2015

      Albenza

      Albendazole

      Anthelminthic

      Anedra pharms

      06/11/2015

      Codeine phosphate / chlorphenamine maleate compound sustained-release reagent

      Codeine phosphate / chlorphenamine maleate compound sustained-release reagent

      Cough caused by upper respiratory tract infection

      Spriaso LLC

      06/22/2015

      Linezolid

      Linezolid

      Treatment of gram positive infections caused by Gram positive bacteria

      Hospira INC

      06/18/2015

               FDA approval of the new drug is mainly based on the type of drug chemistry and therapeutic potential to classify. New drugs by chemical types are mainly divided into: 1 new molecular entities (NME), the most innovative. The active ingredient in the United States, which has never been used as a drug in the United States, can be a single component or a part of a solid, heterogeneous mixture; 2 new derivatives. From has been listed on the active components (i.e., the so-called "patent") medicine chemical derivatization, is already listed in the United States active ingredients of ester, salt, or other non covalent bond derivative of, or to a radical modification of the parent compounds were not approved in the United States listed the; three kinds of new dosage forms. A new formulation or a new formulation containing the active ingredients of the active ingredient, which can be adapted to the same as the market, may also be different; 4 new compositions. Two or more than two kinds of active ingredients listed, there is no such combination of listed products; 5 new specifications or new manufacturers of drugs; 6 new indications. A copy of the approved or marketed by the same company or other company in the United States; the 7 category has been listed but not approved by NDA. Indications have been the same as the listed products, but also different; the 8 Category of non prescription drugs; 10 different types of new drug application.

      Copyright 2015 Nanjing Tianyuexing Bio-tech Co., Ltd. All rights reserved. Supported by www.hxchem.net
      国产伦精品一区二区三区妓女_少妇人妻无码高清_国产av中文字幕无码高清_久久久国产精品播放
      <code id="z5ntm"></code><u id="z5ntm"></u>
      1. <b id="z5ntm"></b>